EUROPEAN PRECISION MEDICINE 2017: NOW AND BEYOND
What it is about :
Precision approach to medicine includes an individual’s genetic profile to guide decisions made in regard to the prevention, better diagnoses, earlier interventions, more-efficient drug therapies, customized treatment plans. Precision medicine provides a genomic blueprint to determine each person’s unique disease susceptibility, define preventive measures and enable targeted therapies in order to promote overall wellness.
KEY PRACTICAL POINTS OF THE CONFERENCE:
– The present and future of Precision Medicine in Europe
– Development and Implementation of Precision Medicine in Europe
– Opportunities to improve Healthcare
– New scientific knowledge, tools, methods and technologies
– Novel approaches to go above and beyond oncology
– Data Standardization
– Financing and Costs
– Commercialization of Precision Medicine
– Benefits for the Pharmaceutical Industry
– Ethical questions
*The number of participants (excluding the speakers) is limited to 150, therefore please, register as early as possible.
To discuss the attendee opportunities or register for the event please contact:
Tel.: +420 226 633 310
E-mail address: firstname.lastname@example.org
To get assistance with booking a room and arranging your flight tickets please contact:
Tel.: +420 777 672 154
E-mail address: email@example.com
Alain van Gool
Professor Personalized Healthcare, Chair of Biomarker Platform
Radboud university medical center, EATRIS
Bioindustry Park Silvano Fumero SpA
Laboratory for Advanced Genomics at RBI
Ph.D., Global Vice President of Health Sciences
European Funding Officer
Regional Foundation for Biomedical Research
Ph.D., Director of Disruptive Technologies
Manager Global Regulatory Affairs, Biomarkers and Diagnostics
Translational Sciences Oncology
Senior Project Leader and Senior PI
Senior Clinical Research Scientist
SolClin Soliman Clinical Research Consulting
Professor of Personalized Healthcare, Radboudumc; Chair of Biomarker Platform, EATRIS Alain van Gool is a professor of Personalized Healthcare at Radboud University Medical Center and an applied biomarker scientist at Netherlands Institute for Applied Scientific Research (TNO), with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. His professional background since 1991 is a mix of academia, pharmaceutical industry, applied research institutes, university medical centers. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. While working in Europe, USA and Asia, he and his teams contributed to over 200 projects in various phases of biomarker R&D. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development, and applications in translational scientific research. Alain is a strong believer of open innovation networks and in his roles he has been collaborating with pharmaceutical, biotechnological, nutriceutical and diagnostic industries, SMEs, biobanks, clinicians, technology providers and information specialists to translate basic research to applied science through public-private partnerships. With that background, he currently heads the Radboudumc center for proteomics, glycomics & metabolomics, coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences) and is chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine) and is co-initiator of Health-RI (the Netherlands Personalized Medicine and Health Research Infrastructure), thus contributing to the organization and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to several scientific advisory boards of start-up entrepreneurs, multinational companies, diagnostic organizations and conference organizers, and is part of several editorial boards of scientific journals.
Fabrizio Conicella has more than 20 years of experience managing organizations and R&D and technology transfer projects. In 1999 he became a Project Manager and Business Developer of Bioindustry Park Silvano Fumero. Since 2001 he was working as a Director of Business development and International Projects and a manager of bioPmed innovation cluster. He is now a General Manager of Bioindustry Park. Since 2011 he has been working as a contract professor both at Università di Torino and Università Piemonte Orientale in business planning, innovation management and technology transfer. He was also a President of Ephoran-MIS, a company specializing in imaging services, and he is now a member of the managing board of KITE association, member of the managing board of 2I3T, the incubator of Università di Torino, member of the managing board of APSTI – Italia Association of Science Parks, member of “Science-Industry” committee of Genopole (F) and an executive vice president of bioPmed cluster association. In the last years he has been a member of Associazione Italia start-up managing board, Assobiotec managing board and Eurotransbio Advisory Board. He has been also appointed as a member of different boards, working groups, evaluator of initiatives, projects and business plans by private and public national and international organizations.
Ph.D., Laboratory for Advanced Genomics at RBI, Rudjer Boskovic Institute Oliver Vugrek graduated in Biology at the Albert Einstein University of Ulm in 1992, and researched for a PhD at the Max Planck Institute for Cellbiology, presenting his thesis in November 1995 at the Karl Ruprechts University of Heidelberg, Germany. In 1996 he was granted a 2-year postdoctoral fellowship at the Australian National University in Canberra. After his postdoc term he was employed as assistant at the RuđerBošković Institute (RBI) in 1999. From 2012 to 2015 he was appointed Head of the Department of Molecular Medicine. He is highly familiar with recombinant DNA technology, and new technologies such as microarrays, and next-generation sequencing. Throughout his research he participated in the discovery of a new metabolic disease in human, S-Adenosylhomocysteine hydrolase (SAHH) deficiency. A major achievement so far is leading FP7 project InnoMol, the largest project ever conducted in Croatia in Natural Sciences thus helping to introduce new technologies and valuable infrastructure in several life science departments at RBI. Subsequently, he has assembled a State-of-the-Art operational Next-Generation-Sequencing facility bringing genomics research at RBI to a new level. At present moment he is leading the Laboratory for Advanced Genomics at RBI.
Jonathan Sheldon, Ph.D., is Global Vice President Healthcare and responsible for Oracle’s healthcare business globally within the Health Sciences Global Business Unit which includes solutions in the areas of precision medicine, population health and convergence with Life Sciences. Previously, Dr. Sheldon has held positions of both Chief Scientific Officer and Chief Technology Officer in software companies serving both life science and healthcare sectors where he has lead the company overall strategic direction. Prior to the software industry, Dr. Sheldon was Head of Bioinformatics for five years at Roche (UK) Pharmaceuticals. Dr Sheldon has being an invited speaker at over a 100 international conferences and served on various advisory groups and boards including as a Director of the tranSMART Foundation. Most recently, Dr Sheldon was appointed to serve as a Director on the Board of DIA Dr. Sheldon holds a Ph.D. in Molecular Biology/Biochemistry from the University of Cambridge
After Gianni D’Errico graduated cum laude at University Federico II in Napoli and obtained his post graduate master’s degree in project management at SIOI in Rome, he started working in Brussels as R&D project developer and then in Maribor, where he got acquainted with R&D programs and innovative projects in Life Sciences. In Slovenia he cooperated with the University of Maribor, providing lectures to PhD students on IP issues within R&D international projects. Since September 2015 he has been working at the Regional Foundation for Biomedical Research (a strategic agency specialized in financing highly scientific projects in Life Sciences), where he is in charge of the European strategy, programs and projects with the aim to create synergies between Lombardy and other European regions’ R&D&I policies. He is member of the IC-PERMED Executive Committee, main facilitator of the ESTHER (Emerging and Strategic Technologies for Healthcare) Interregional cooperation group, and he has been implementing the participation of the Lombardy Region to TRANSCAN 2 and PERMED ERA-NET. He is in charge of regional innovation policies for AHA and of the implementation of gender guidelines among Research Funding and Research Performing Organizations
Helena is Director of Disruptive Technologies at Elsevier in Cambridge MA, where she makes use of big data and data science solutions to ease the translation of basic biology research insights into precision medicine actionability with a special focus and passion for the oncology problem space. Before that, she was Associate Director of Data Sciences at Foundation Medicine where she led a team of data scientists and engineers tasked with integration, management, standardization, reuse and analysis of the company’s knowledgebase (FoundationCORE). Helena has published more than 30 papers and received the 2013 Big Data award in the Semantic Web Challenge at the International Semantic Web Conference. Helena received her Ph.D. in Bioinformatics from the Universidade Nova de Lisboa.
Dr. Maria Chatzou holds a PhD in Biomedicine, MSc in Bioinformatics and a BSc in Computer Science and Biomedical Informatics. Maria is a biotech innovator and a proud geek, expert in bioinformatics, medical informatics and high performance computing (HPC). She is also a passionate entrepreneur and founder and President of Innovation Forum Barcelona. As a researcher at the Centre for Genomic Regulation(CRG), in Barcelona, Spain, she has been designing and deploying tools and methods that facilitate the analysis of Big Biomedical Data, allow for biological discoveries, and promote personalized medicine. She is part of the developing team of Nextflow, a programming framework that is revolutionizing the computational analysis of genomic data and setting the foundations for personalized medicine computational analyses. Maria is also a frequent industry speaker and has spoken in many international conferences on the subjects of docker containers, genomics workflows, the computational challenges of personalized medicine, and HPC in genomics, as well as scientific innovation, leadership and entrepreneurship among many other topics.
Dr. Svetlana Mukhina is Manager Global Regulatory Affairs, Biomarkers and Diagnostics at Merck KGaA, where she is leading global CDx regulatory activities for two development programs. In this role, she closely works with companion diagnostic development manufacturers and internal stakeholders to develop regulatory strategies enabling IVD / therapeutic codevelopment. Svetlana holds a PhD in Biology and an MSc in Regulatory Affairs, with a focus on regulation of in vitro companion diagnostic devices in the US. Overall, she has 16+ year experience in molecular oncology, drug discovery, and assay development.
Andrew Pierce is an associate director of Translational Science Oncology at AstraZeneca, with a focus on implementing biomarkers in early phase clinical development to inform drug dose/scheduling, mechanism of action and patient selection.
Bio coming soon
Bio coming soon